Why the study?
Cardiac amyloidosis is an under-recognized cause of left-ventricular hypertrophy often misclassified as hypertrophic cardiomyopathy or hypertensive heart disease, driving the need for an AI model to distinguish these etiologies.
Does an AI model integrating ECG and echocardiography accurately diagnose cardiac amyloidosis among patients with left-ventricular hypertrophy?
Comparison
AI model (Super Learner) and simplified scoring system vs clinical diagnoses
Design
Retrospective multicenter diagnostic model development and external validation study
Key result
A Super Learner AI model integrating electrocardiogram and echocardiography features accurately distinguished cardiac amyloidosis from other causes of left-ventricular hypertrophy with an AUC of 0.97.
Authors
Loading...
High AUC supports ML ensembles for CA discrimination in cohorts; leaves open prospective validation before clinical use.
Cross-Sectional (n=1,221)
Yes
Does an AI model integrating ECG and echocardiography accurately diagnose cardiac amyloidosis among patients with left-ventricular hypertrophy?
Effect estimate: AUC 0.97 (95% CI 0.95-0.98)
An AI model and simplified scoring system using routine ECG and echocardiography parameters can accurately distinguish cardiac amyloidosis from other causes of left ventricular hypertrophy.
Zhang et al. (2026) conducted a cross-sectional in Cardiac amyloidosis (n=1,221). Super Learner AI model was evaluated on Diagnostic accuracy (AUC) for cardiac amyloidosis (AUC 0.97, 95% CI 0.95-0.98). A Super Learner AI model integrating electrocardiogram and echocardiography features accurately distinguished cardiac amyloidosis from other causes of left-ventricular hypertrophy with an AUC of 0.97.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: